First tranche of STP investment announced by health secretary and NHS England
The Pharmaceutical Journal, 20 July 2017

£325 million in funding for sustainability and transformation partnerships (STPs) by Health Secretary Jeremy Hunt. The announcement gave the green light to capital investment in 15 local areas. Hunt said that the funding will “support strong local plans to help the NHS modernise and transform care for patients”. The strongest STPs, which are those that received the funding, achieved across the three STP metrics: hospital performance, patient-focused change, and transformation.

May promises business leaders no Brexit ‘cliff edge’ for companies
The Pharmaceutical Journal, Debbie Andalo, 19 July 2017

Theresa May has publicly pledged to business that she will not let companies fall off a Brexit ‘cliff edge’. Paul Polman, CEO of Unilever, said that business had been pushing for a longer transition period, which is now becoming “more realistic”. Civil servants briefed afterwards that the ultimate deal would like to see Britain “close but not in” the single market and the customs union. Downing Street is considering (particularly for the medicines industry) regulatory authorisations to make it easier for firms to operate in the EU after Brexit. The article finished by noting that Chancellor Philip Hammond said that there is “pretty much agreement around the cabinet table” about the necessity of a transitional deal.


House of Commons Questions – July 20, 2017


Tom Brake MP:

To ask the Secretary of State for Exiting the European Union, what assessment the Government has made of the effect on access to newly developed drugs and treatments of the UK ceasing to be a member of the European Medicines Agency.

Department of Health Response

 Robin Walker MP:

As part of the negotiations the Government will discuss with the EU and Member States how best to continue cooperation in the field of medicines regulation in the best interests of business, citizens and patients in the UK and the EU.
We recognise the importance of a close cooperative relationship between the UK and EU in the field of medicines regulation and science and research collaboration.


Pauline Latham MP:

What funding is available for treatments which have been made available under the Early Access to Medicines Scheme after marketing authorisation but before the publication of NICE guidance.

Department of Health Response 

Steve Brine MP:

The Early Access to Medicines Schemes is a voluntary scheme. Companies are not paid for the medicines they supply into the scheme. However, the Government has recently announced new funding as part of a of a wider package of up to £86 million aimed at addressing barriers to uptake of innovation that were recommended in the Accelerated Access Review. Small to Medium Enterprises with products that meet the requirements for the Early Access to Medicines Scheme will be able to access this funding opportunity. Further announcements will be made on how small businesses can apply for this support. More information can be found at this link:



First tranche of STP investment announced by health secretary and NHS England
The Pharmaceutical Journal, 20 July 2017

Funding worth £325m has been announced to support sustainability and transformation partnerships (STPs) by health secretary Jeremy Hunt and NHS England chief executive Simon Stevens.

The announcement, which saw Hunt and Stevens give the green light to local capital investment schemes in 15 areas of the country, was made at the King’s Fund on 19 July 2017. They included the biggest awards of £50m to go towards improvements in urgent and emergency care in Greater Manchester and £30m–£50m to go towards a new cancer centre in Cumbria that will improve access to chemo and radiotherapy.

According to NHS England, the initiative of this funding programme, which was secured in the budget in March, has been targeted at the STPs with the strongest and most advanced schemes. However, the government has also committed to make further capital investment available in the autumn.

Hunt said that there are already excellent examples of improvements being made in local areas and that this money will enable these improvements to be made even faster. “This funding will support strong local plans to help the NHS modernise and transform care for patients,” he said.

According to Stevens, the stronger STPs have performed well across three broad areas — hospital performance, patient-focused change and transformation.

“This is fantastic news for patients in Cumbria,” said West, North and East Cumbria Health and Care Partnership (STP) lead, Stephen Eames. “This significant investment in our local cancer services — in partnership with the excellent specialist services at Newcastle hospitals — means we can provide more modern cancer treatment from state of the art facilities, which will benefit people living across north Cumbria,” he added.

From Factory to Pharmacy

As part of our mission to build awareness, understanding and appreciation of the vital importance of the healthcare distribution sector, we developed an infographic explaining the availability of medicines. It identifies the factors that can impact drug supply, as well as the measures that HDA members undertake day in, day out to help mitigate the risks of patients not receiving their medicines.

See the Infographic

Apply to become a Member

Membership of the HDA guarantees your organisation:

  • Access to leading policy and industry forums of debate and discussion
  • Invitations to a range of networking industry events organised through the year, including an Annual Conference and a Business Day
  • Representation on HDA working parties, including the Members’ Liaison Group
  • A daily Political and Media Bulletin and HDA Newsletters
  • Access to HDA policy documents and all sections of the HDA website
  • Branding and marketing opportunities
Apply Now

Already a Member?